Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
4.31 (USD) • At close April 25, 2025
Overview | Financials
Cijfers zijn in miljoenen (behalve de cijfers per aandeel en de ratio's) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Operationele Activiteiten: | |||||||||
| Nettowinst
| -54.836 | -62.255 | -94.66 | -94.66 | -122.725 | -91.14 | -60.08 | -26.554 | -13.209 |
| Afschrijvingen & Amortisatie
| 12.625 | 13.16 | 12.668 | 12.668 | 1.879 | 1.467 | 0.32 | 0.177 | 0.116 |
| Uitgestelde Inkomstenbelasting
| -2.268 | -1.249 | -1.424 | -1.424 | 1.115 | 0.536 | -0.414 | 0 | 0 |
| Aandelen Gebaseerde Vergoedingen
| 18.363 | 10.716 | 12.16 | 11.381 | 8.273 | 6.484 | 1.728 | 0.499 | 0.54 |
| Verandering in Werkkapitaal
| -8.82 | -6.294 | -35.15 | -35.15 | 11.854 | -2.798 | 1.607 | 1.121 | -3.583 |
| Vorderingen
| -1.218 | -8.367 | -13.374 | -13.374 | -6.237 | -2.182 | -1.67 | -1.098 | 0.204 |
| Voorraden
| -8.782 | -14.804 | -7.465 | -7.465 | -7.418 | -5.143 | 4.042 | 1.698 | -0.846 |
| Crediteuren
| -9.613 | 6.959 | -4.318 | -4.318 | 5.527 | -2.486 | -1.11 | 0.661 | -2.909 |
| Overig Werkkapitaal
| 10.793 | 9.918 | -9.993 | -9.993 | 19.982 | 7.013 | 0.345 | -0.14 | -0.032 |
| Overige Niet-Contante Posten
| -2.045 | -1.101 | 3.515 | 3.515 | 0.961 | 3.104 | 0.56 | 0.094 | 0.049 |
| Kasstroom uit Operationele Activiteiten
| -36.981 | -47.023 | -102.891 | -102.891 | -95.535 | -80.558 | -56.279 | -24.663 | -16.087 |
| Investeringsactiviteiten: | |||||||||
| Investeringen in Materiële Vaste Activa
| -0.868 | -2.263 | -0.524 | -0.524 | -1.085 | -0.377 | -1.51 | -0.7 | -0.035 |
| Netto Overnames
| 0 | 0 | 0 | 38.469 | 38.469 | 0.377 | 0 | 0 | 0 |
| Aankoop van Beleggingen
| -34.485 | -43.741 | 0 | -43.02 | -43.02 | -101.773 | -68.851 | 0 | 0 |
| Verkoop/verval van Beleggingen
| 40.236 | 40 | 34.985 | 34.985 | 103.6 | 74.745 | 2.1 | 0 | 0 |
| Overige Investeringsactiviteiten
| 0 | 0 | 34.985 | 4.551 | -27.028 | -0.377 | -66.751 | 0 | 0 |
| Kasstroom uit Investeringsactiviteiten
| 4.883 | -6.004 | 34.461 | 34.461 | 97.964 | -27.405 | -68.261 | -0.7 | -0.035 |
| Financieringsactiviteiten: | |||||||||
| Schuldaflossingen
| 38.169 | 0 | 102.718 | 0 | 69.75 | 25 | 35 | 0 | -0.032 |
| Uitgifte van Gewone Aandelen
| 0 | 0 | 30 | 27 | 65.891 | 61.692 | 98.325 | 0.159 | 0.071 |
| Terugkoop van Gewone Aandelen
| -3.734 | -1.009 | -0.468 | -0.534 | -0.063 | 0 | 0 | 0 | 0 |
| Uitgekeerde Dividenden
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overige Financieringsactiviteiten
| 1.733 | -0.604 | -4.777 | 0.781 | -9.514 | 55.53 | 4.105 | 35.139 | 3.936 |
| Kasstroom uit Financieringsactiviteiten
| 36.168 | -1.613 | 127.473 | 127.473 | 27.247 | 126.064 | 128.211 | 35.139 | 3.904 |
| Overige Informatie: | |||||||||
| Effect van Wisselkoersveranderingen op Kas
| 0 | 0 | 0 | -0.003 | -0.003 | -0.022 | 0 | 0 | 0 |
| Netto Kasstroomverandering
| 4.07 | -54.64 | 59.043 | 59.043 | 29.673 | 18.079 | 3.671 | 9.776 | -12.218 |
| Kaspositie aan het Einde van de Periode
| 75.744 | 71.674 | 126.314 | 126.314 | 67.271 | 37.598 | 45.716 | 42.045 | 32.269 |